Figure 1

Figure 1

Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4 Mutations

Format

PNG

Quelle:

X4 Pharmaceuticals

Downloads